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PERSPECTIVE
Interferon associated retinopathy
Seiji Hayasaka, Yasunori Nagaki, Masayuki Matsumoto, Shoichi Sato
Interferon associated retinopathy has been increasingly
reported in Japan. In fact, most reports have appeared in
the Japanese literature. In the present study, we review
these articles.
Interferon was originally described as a factor capable of
inducing antiviral activity.1 Since then, the factor has been
found to have antitumour activity in human neoplasms
including metastatic renal cell carcinoma,2 skin
melanoma,3 Kaposi’s sarcoma,4 and haemangiomatosis.5
The agent also inhibits vascular endothelial cells6 and
regressed experimental iris neovascularisation.7 In Europe,
interferon has been used in an attempt to treat dendritic
keratitis.8 In the USA, it has been used mainly to treat sub-
retinal neovascularisation in age related macular
degeneration.9–11 In Australia, antifibrotic eVects of inter-
feron have been employed to treat glaucoma filtering
surgery and to manage ocular cicatricial pemphigoid.12 13
Interferons have been clinically used in the treatment of
viral and malignant diseases. Subsequently, a variety of
adverse eVects of interferon use has been reported.14 Que-
sada et al 14 noted toxic reactions from interferon, including
acute side eVects of an influenza-like syndrome consisting
of fever, chills, myalgias, arthralgias, and headache. Fatigue
has been the most prevalent chronic toxicity. Toxicities of
the central nervous system, haematopoietic system,
gastrointestine, renal function, skin, cardiovascular system,
musculoskeletal system, and endocrine also have been
described. However, these authors did not mention the
ocular toxicity.14
Typical interferon associated retinopathy
In 1990, Ikebe and associates15 first reported a 39 year old
patient with retinal haemorrhages and cotton wool spots
following intravenous administration of interferon. Since
1992, interferon therapy for viral hepatitis has been used at
many hospitals in Japan; there are possibly more than 1.6
million patients with type C hepatitis in Japan and
interferon use has been allowed by Health Insurance of
Japan. Since 1993, ocular complications following inter-
feron therapy have been reported mainly in Japan,16–47
although Bauherz and associates,48 Guyer and coworkers,11
Klose et al,49 and Vegh et al 50 have also demonstrated inter-
feron associated ocular toxicity.
Typical ocular lesions include cotton wool spots and
retinal haemorrhages at the posterior fundus, particularly
around the optic disc.16 21 22 32 37 40 43 Cotton wool spots and
retinal haemorrhages may occur alone or together.37 42
Retinal haemorrhages appear as superficial linear and
patchy forms or as white centred bleeding. The retinopathy
may develop unilaterally or bilaterally.37 Blocking of back-
ground fluorescence by retinal haemorrhages and non-
perfused areas at the cotton wool spots can be seen by
fluorescein angiography.21 37
An initial dose (3 × 106, 6 × 106, or 9 × 106 U/day) of
interferon is usually administered intravenously or intra-
muscularly three or six times per week for several weeks,
and then the agent is gradually tapered. The retinopathy
has reportedly developed 28 to 94 days,17 2 weeks to 5
months,21 2 weeks to 3 months,22 43 2–18 weeks,35 and 2–15
weeks42 after initiation of interferon therapy. The retino-
pathy may disappear spontaneously during therapy or rap-
idly after stopping therapy.17 21 22 29 37 Despite the retin-
opathy, subjective complaints have been uncommon, and
visual acuity has not always been impaired.21 22 29 37 Most
patients with interferon associated retinopathy can con-
tinue with the planned course of interferon therapy.
A large scale study of the incidence of interferon associ-
ated retinopathy has not been performed. Incidences of
retinopathy in patients receiving interferon have been
reported to be 18% (2/11),25 35.5% (12/34),43 40% (8/20,16
18/4520), 42% (10/24),35 46% (23/50),32 50% (10/20),26
61% (45/74),22 73.3% (22/30),44 and 86% (43/50).40 The
incidence is thought to depend on the initial dose of
interferon.21 29 37 42 Particularly, patients receiving inter-
feron, 9 × 106 U/day, six times per week, have shown a high
frequency of retinopathy (Table 1).42 The incidence also
depends on the presence of diabetes mellitus (Table 1):
patients with diabetes have shown a high frequency of
retinopathy.16 22 32 37 40 42 Also, the incidence is possibly
influenced by the frequency of fundus examination,40
because the subtle retinopathy may disappear after the
long intervals between examinations. The incidences of
interferon associated retinopathy in patients with type B
hepatitis and malignant diseases are roughly similar to
those with type C hepatitis.21 22 No diVerence in the
incidence of retinopathy between interferon alfa and beta
has been found.28 46
Atypical interferon associated ocular complications
In addition to retinal haemorrhages and cotton wool spots,
uncommon ocular lesions develop after the start of
Table 1 Initial dose of interferon alfa-2b
Initial dose of interferon alfa-2b (U/day, 6
times per week)
Patents without diabetes mellitus (n=49) Patients with diabetes mellitus (n=9)
Retinopathy Retinopathy
Absent (n=30) Developed (n=19) Absent (n=2) Developed (n=7)
3 × 106 13 4 (23%) 2 0 (0%)*
6 × 106 11 6 (35%) 0 3 (100%)*
9 × 106 6 9 (60%) 0 4 (100%)*
*p<0.01, Kruskal–Wallis rank test, adapted from Hayasaka et al.42
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interferon therapy. Visual acuities in patients with the
atypical toxicity of interferon have sometimes been
impaired.
Kado and coworkers18 reported on a 61 year old woman
with type C hepatitis who received interferon alfa 6 × 106
U/day. The patient had vitreous haemorrhage in the left
eye, and her left visual acuity decreased to 0.01.Miyamoto
and associates17 described a 27 year old woman with type C
chronic hepatitis and sarcoidosis who was receiving
interferon alfa. The patient complained of visible floaters
in both eyes 38 days after starting interferon therapy. Iridial
nodules, cells and snowball opacities in the vitreous, and
periphlebitis in the retina were found. The authors
believed that deterioration of sarcoidosis associated uveitis
may have been induced by interferon alfa.17 Kubo and
associates31 showed prolonged retinal changes in a patient
with type C hepatitis after interferon had been discontin-
ued. Chen et al 43 reported on a patient in whom
retinopathy did not resolve for a long time after the start of
interferon therapy. This patient had chronic active hepati-
tis, diabetes mellitus, and systemic hypertension. The
authors recommended that periodic fundus examinations
be performed during a patient’s interferon therapy.43 Reti-
nal microaneurysms have also been found in patients
receiving interferon alfa.22 32 37 Hayasaka et al 37 found sub-
conjunctival haemorrhages in three patients treated with
interferon alfa. Bauherz et al 48 described bilateral oculo-
motor nerve paralysis induced by interferon alfa in a
patient with hairy cell leukaemia. Yoshitoshi and
associates23 reported a 65 year old woman with type C
chronic active hepatitis in whom panophthalmitis devel-
oped 6 days after interferon alfa 107 U/day. The patient’s
right eye was enucleated. Histopathological study showed
massive infiltration of inflammatory cells in the ocular tis-
sues. The bacterial culture was negative. The authors
believed that immunological dysfunction may have been
involved in the pathogenesis of panophthalmitis in this
patient.23 Ayaki34 reported on a 56 year old man with type
C hepatitis and diabetes mellitus in whom neovascular
glaucoma in the left eye developed 2 months after the start
of interferon alfa 6 × 106 U/day, three times a week. He
believed that interferon may have been a factor in the
development of neovascular glaucoma in this patient.
Miyamura et al 27 and Saitoh et al 30 described aggravation
of diabetic retinopathy in patients treated with interferon
for chronic type C hepatitis. Kawamoto et al 28 reported
central retinal vein occlusion in three patients treated with
interferon. Branch retinal vein occlusion occurred in two
patients during interferon therapy.17 41 The patients had
decreased visual acuity in the aVected eyes.17 41 A patient
with branch retinal artery occlusion during interferon
therapy was reported.22
Preretinal haemorrhage associated with sudden visual
impairment occurred during interferon therapy.39
Tadokoro and associates38 reported on a 41 year old man
with type C active hepatitis in whom optic disc oedema in
the left eye developed after initiation of interferon therapy.
His visual acuity was not impaired.Despite continuation of
interferon therapy, the disc oedema gradually decreased.
The authors believed that the use of interferon may have
been related to the disc oedema.38
Atypical interferon associated ocular complications have
been found in a small number of patients. The single
reports may represent coincidences and not have any
association with interferon use. For instance, two cases of
branch retinal vein occlusion may be the expected finding
in the population treated. The visual acuity in patients with
atypical complications may sometimes be impaired.
Typical interferon associated retinopathy develops mainly
in the first 3 months, and atypical toxicities occur during
the therapy. Patients should be examined before starting
interferon to look for pre-existing retinopathy; if any is
present, interferon should not be used or the patient
should be monitored closely—for example, monthly. If no
retinopathy is present, less frequent examinations may be
performed, such as at 3 months, unless the patient notes
decreased vision. The treatment should be discontinued if
visual acuity decreases or severe ocular toxicity occurs.
Risk factors and pathogenesis of interferon
associated retinopathy
Diabetes mellitus is reportedly a risk factor in the develop-
ment and progression of interferon associated
retinopathy.16 22 27 30 32 37 40 42 45
Systemic hypertension has also been suspected in the
development of the retinopathy.21 32 40 Patients’ age,35 37 40
arterial sclerosis,31 erythrocyte count,22 32 leucocyte count,22
platelet count,16 18 19 29 46 haemoglobin,21 29 46 serum gluta-
mate oxaloacetate transaminase,22 serum glutamate pyru-
vate transaminase,22 28 36 triglyceride,40 and total
cholesterol40 levels have been examined as possible risk
factors, but the results have been negative or inconclusive.
Pathogenesis of interferon associated retinopathy is
unknown, although some investigators have suggested
deposition of the immune complex at the vessels17 and
immunological dysfunction.23 To our knowledge, no
histopathological study of typical interferon associated
retinopathy has been done.
Animal experiments for ocular toxicity of interferon
Vegh and coworkers50 investigated the toxicity of injecting
human fibroblast interferon intravitreally in rabbit eyes,
and found that a single intravitreal injection of 166 660
U/0.1 ml was non-toxic to ocular structures as demon-
strated by electroretinographic and histological examin-
ation. Abe and associates51 studied the long term adminis-
tration of interferon to mice. Their results showed that the
retinal vascular bed was occluded in mice that were
pretreated with urethane but not in mice without pretreat-
ment. The authors believed that a diseased retina is a pre-
requisite for the development of retinal vessel occlusion
with interferon.51
Hepatitis C virus associated retinopathy
Abe and associates52–54 reported on patients with possible
hepatitis C virus associated retinopathy. Retinal haemor-
rhages and cotton wool spots developed in patients with
chronic hepatitis C virus infection unassociated with inter-
feron therapy.52–54 To our knowledge, no other investigators
have reported hepatitis C virus associated retinopathy. It is
possible that the pathogeneses of interferon associated
retinopathy and hepatitis C virus associated retinopathy
may be related. Also, it is probable that pre-existing retinal
vascular disease, such as diabetes or retinopathy associated
with hepatitis C, may predispose one to develop retino-
pathy secondary to interferon.
Conclusion
Two weeks to 3 months after the start of interferon
therapy, retinal haemorrhages and cotton wool spots
develop. The incidence of retinopathy depends on the ini-
tial dose of interferon. The retinopathy disappears sponta-
neously during therapy or rapidly after stopping the
therapy. Despite the retinopathy, most patients have had
good visual acuity. However, a small number of patients
have had impaired vision. In particular, patients with
diabetes mellitus have shown a high frequency of develop-
ment and progression of retinopathy during interferon
therapy. Patients should be examined before starting inter-
feron to look for pre-existing retinopathy. If any is present,
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interferon should not be used or the patient should be
monitored closely—for example, monthly. If no retino-
pathy is present, less frequent examinations might be per-
formed, such as at 3 months, unless the patient notes
decreased vision. If severe ocular toxicity occurs, interferon
therapy should be discontinued.
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